Spyros Papapetropoulos

Learn More
Migraine is a prevalent disabling neurological disorder associated with a wide range of medical and psychiatric comorbidities. Population- and clinic-based studies suggest that psychiatric comorbidities, particularly mood and anxiety disorders, are more common among persons with chronic migraine than among those with episodic migraine. Additional studies(More)
BACKGROUND Chronic migraine is a neurological condition with a large individual and socioeconomic burden of disease. The recently completed Phase III REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical development program established the efficacy and safety of onabotulinumtoxinA as a prophylactic treatment for chronic migraine patients.(More)
Increasing evidence supports a role for abnormal immune activation and inflammatory responses in Huntington disease (HD). In this study, we evaluated the therapeutic potential of laquinimod (1 and 10 mg/kg), a novel immunomodulatory agent shown to be protective in a number of neuroinflammatory conditions, in the YAC128 mouse model of HD. Treatment with(More)
More than one million people in the US (five million people worldwide) are believed to have Parkinson's disease, and its prevalence is expected to double by 2030 (1). The national annual economic burden for Parkinson's disease in 2010 was estimated at more than $14.4B and is expected to grow substantially due to the increasing aging population (2). Disease(More)
  • 1